CEL-SCI (CVM) said Friday it closed a $5 million underwritten public offering of shares.
The company sold 2 million shares at $2.50 each in the offering.
CEL-SCI said it granted underwriters a 45-day option to buy up to an additional 190,000 shares to cover overallotments.
Net proceeds will be used for developing its investigational cancer treatment, Multikine, general corporate purposes, and working capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.